Drugs / QXL138AM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06582017 | Aug 2024 → Dec 2027 expected | breast cancer, hepatocellular carcinoma, lung cancer, malignant pancreatic neoplasm +4 | Nammi Therapeutics Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QXL138AM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06582017 ↗ |
| Modality | Protein / enzyme biologic | “masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a” NCT06582017 ↗ |
| Route | Intravenous | “QXL138AM Injection every 2 weeks by IV Infusion” NCT06582017 ↗ |